Hematologic Malignancy
Enteropathy-Associated T-Cell Lymphoma
CI-CAN-00008862EATLExplore in graph →
Hematologic8 active trials
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00008862EATLExplore in graph →
Clinical trials
27 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (5)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06692452 | Tazemetostat Plus CHOP in 1L T-cell Lymphoma | withdrawn | Phase 2 | 0 | Eric Jacobsen, MDOTHER | 0 | Apr 1, 2026 | clinicaltrials |
| NCT04795869 | Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT04639843 |
| Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma |
| withdrawn |
| Phase 1 |
| 0 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Nov 4, 2022 |
| clinicaltrials |
Data updated 23 days agoSource updated Apr 1, 2026source: clinicaltrials